KRAS and cancer: Pharmacological and molecular inhibitions of GSK-3β in K-ras-mutant PDAC cancer models showed upregulation of c-Myc and β-catenin leading to apoptosis induction, and indicative treatment selection of only malignant pancreatic epithelial cells [21,39].